Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 148Myelodysplastic Syndromes 116Leukemia 115Precursor Cell Lymphoblastic Leukemia-Lymphoma 95Lymphoma 86Lymphoma, Non-Hodgkin 80Multiple Myeloma 74Hodgkin Disease 68Leukemia, Lymphocytic, Chronic, B-Cell 61Lymphoma, Large B-Cell, Diffuse 52Myeloproliferative Disorders 51Congenital Abnormalities 51Leukemia, Myeloid, Chronic-Phase 50Lymphoma, Follicular 47Leukemia, Myeloid, Accelerated Phase 47Neoplasms, Plasma Cell 46Lymphoma, Mantle-Cell 43Leukemia, Myelomonocytic, Chronic 43Burkitt Lymphoma 42Lymphoma, B-Cell, Marginal Zone 41Lymphoma, Large-Cell, Immunoblastic 39Leukemia, Myelogenous, Chronic, BCR-ABL Positive 39Blast Crisis 39Primary Myelofibrosis 36Recurrence 33Anemia, Refractory, with Excess of Blasts 33Hematologic Neoplasms 32Myelodysplastic-Myeloproliferative Diseases 31Graft vs Host Disease 31Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 28

Interventions

Lenalidomide 3Dexamethasone 3ixazomib 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Radiotherapy 2Calcium Dobesilate 2pomalidomide 1daratumumab 1cc-486 1Thalidomide 1Sodium Selenite 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Immunotherapy, Adoptive 1Gemcitabine 1Drug Combinations 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Plasmacytoma × Busulfan × Clear all
NCT02506959 2025-03-18

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

M.D. Anderson Cancer Center

Phase 2 Completed
83 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡